Blue Trust Inc
CHRS icon

Blue Trust Inc’s Coherus Oncology CHRS Stock Holding History

Blue Trust Inc’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2 Buy
+2
New +$3 ﹤0.01% 2517

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
RE
Rydar Equities Weatherford, Texas $194M AUM 23.21% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Blue Trust Inc's CHRS Position: Q3 2026 in Review

Blue Trust Inc opened a new position in Coherus Oncology (CHRS) in Q3 2026: 2 shares worth $2. The stake represents ﹤0.01% of the portfolio and ranks #2517 among its holdings.

9 funds tracked by Wall St. Rank hold CHRS as of Q3 2026.

  • Blue Trust Inc held 2 shares of Coherus Oncology worth $2 as of Q3 2026.
  • Coherus Oncology was a new Blue Trust Inc position in Q3 2026.
  • Coherus Oncology made up ﹤0.01% of Blue Trust Inc's portfolio in Q3 2026, its #2517 holding.
  • 9 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2026.

Based on Blue Trust Inc's 13F filing for Q3 2026, filed 15 Oct 2026.